person · Reporting owner

Bender Jeremy

Disclosed activity across 5 companies

Tapewire entity: 28118
SEC CIK: 0001863107

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Aura Biosciences, Inc.AURA · Entity 5142	Director	July 07, 2026	July 08, 2026
Bicara Therapeutics Inc.BCAX · Entity 4673	Director	July 28, 2026	July 29, 2026
Mereo BioPharma Group plcMREO · Entity 7264	Director	February 26, 2026	February 27, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Aura Biosciences, Inc.

Report date July 07, 2026 · Filed July 08, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	30,000	Reported balance After 2026-07-07 transaction · row 1 1 source row Row 1 · 2026-07-07 · Grant · Acquired 30,000 · Balance 30,000 F1: These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in three substantially equal annual installments beginning on July 15, 2027, subject to the Reporting Person's continued service as of each such vesting date.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.03 · Expires 2036-07-07	Direct	60,000	Reported balance After 2026-07-07 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-07-07 · Grant · Acquired 60,000 · Balance 60,000 F2: The shares underlying this option vest in three substantially equal annual installments beginning on July 7, 2027, subject to the Reporting Person's continued service as of each such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in three substantially equal annual installments beginning on July 15, 2027, subject to the Reporting Person's continued service as of each such vesting date.

F2: The shares underlying this option vest in three substantially equal annual installments beginning on July 7, 2027, subject to the Reporting Person's continued service as of each such vesting date.

Bicara Therapeutics Inc.

Report date July 28, 2026 · Filed July 29, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.88 · Expires 2036-07-28	Direct	38,950	Reported balance After 2026-07-28 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-07-28 · Grant · Acquired 38,950 · Balance 38,950 F1: One-third of the shares underlying this option shall vest and become exercisable on July 28, 2027, with the remainder vesting in twenty-four equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: One-third of the shares underlying this option shall vest and become exercisable on July 28, 2027, with the remainder vesting in twenty-four equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

Mereo BioPharma Group plc

Report date February 26, 2026 · Filed February 27, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Share Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.39 · Expires 2036-02-26	Direct	66,000	Reported balance After 2026-02-26 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-02-26 · Grant · Acquired 66,000 · Balance 66,000 F1: Vests in substantially equal monthly installments over a one year period from the February 26, 2026 grant date. F2: Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer.
Deferred Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	117,533	Reported balance After 2026-02-26 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-02-26 · Grant · Acquired 117,533 · Balance 117,533 F3: Deferred restricted stock units ("DRSU") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service. F2: Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer.

Filing footnotes · ownership attribution and instrument terms

F1: Vests in substantially equal monthly installments over a one year period from the February 26, 2026 grant date.

F2: Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer.

F3: Deferred restricted stock units ("DRSU") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Day One Biopharmaceuticals, Inc.

Report date April 23, 2026 · Filed April 23, 2026

Section 16 reporting ended · disclosed 2026-04-23. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2026-04-23 transaction · row 1 1 source row Row 1 · 2026-04-23 · Disposition to issuer · Disposed 204,643 · Balance 0 F1: On March 6, 2026, Servier Pharmaceuticals LLC, a Delaware limited liability company ("Parent"), Servier Detroit Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Day One Biopharmaceuticals, Inc., a Delaware corporation (the "Company"), and Servier S.A.S., a French societe par actions simplifiee, solely as a guarantor, entered into an Agreement and Plan of Merger (the "Merger Agreement"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (such merger and the other transactions contemplated by the Merger Agreement, the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent. F2: Upon the closing of the Merger on April 23, 2026, each issued and outstanding share of the Company's Common Stock, par value $0.0001 per share, was either (x) purchased for $21.50 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement, or (y) automatically converted into the right to receive the Offer Price (the "Merger Consideration"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement.
Common StockSEC Table I · non-derivative	IndirectSee footnote	Reported balance After 2026-04-23 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2026-04-23 · Disposition to issuer · Disposed 20,204 · Balance 0 F1: On March 6, 2026, Servier Pharmaceuticals LLC, a Delaware limited liability company ("Parent"), Servier Detroit Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Day One Biopharmaceuticals, Inc., a Delaware corporation (the "Company"), and Servier S.A.S., a French societe par actions simplifiee, solely as a guarantor, entered into an Agreement and Plan of Merger (the "Merger Agreement"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (such merger and the other transactions contemplated by the Merger Agreement, the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent. F2: Upon the closing of the Merger on April 23, 2026, each issued and outstanding share of the Company's Common Stock, par value $0.0001 per share, was either (x) purchased for $21.50 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement, or (y) automatically converted into the right to receive the Offer Price (the "Merger Consideration"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement. F3: Represents shares held by The Jeremy Bender 2023 Grantor Retained Annuity Trust dated June 27, 2023.
Common StockSEC Table I · non-derivative	IndirectSee footnote	Reported balance After 2026-04-23 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 3 · 2026-04-23 · Disposition to issuer · Disposed 300,000 · Balance 0 F1: On March 6, 2026, Servier Pharmaceuticals LLC, a Delaware limited liability company ("Parent"), Servier Detroit Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Day One Biopharmaceuticals, Inc., a Delaware corporation (the "Company"), and Servier S.A.S., a French societe par actions simplifiee, solely as a guarantor, entered into an Agreement and Plan of Merger (the "Merger Agreement"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (such merger and the other transactions contemplated by the Merger Agreement, the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent. F2: Upon the closing of the Merger on April 23, 2026, each issued and outstanding share of the Company's Common Stock, par value $0.0001 per share, was either (x) purchased for $21.50 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement, or (y) automatically converted into the right to receive the Offer Price (the "Merger Consideration"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement. F4: Represents shares held by the Jeremy Bender 2025 Grantor Retained Annuity Trust of which the Reporting Person is trustee.
Common StockSEC Table I · non-derivative	IndirectSee footnote	Reported balance After 2026-04-23 transaction · row 4 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 4 · 2026-04-23 · Disposition to issuer · Disposed 147,702 · Balance 0 F1: On March 6, 2026, Servier Pharmaceuticals LLC, a Delaware limited liability company ("Parent"), Servier Detroit Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Day One Biopharmaceuticals, Inc., a Delaware corporation (the "Company"), and Servier S.A.S., a French societe par actions simplifiee, solely as a guarantor, entered into an Agreement and Plan of Merger (the "Merger Agreement"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (such merger and the other transactions contemplated by the Merger Agreement, the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent. F2: Upon the closing of the Merger on April 23, 2026, each issued and outstanding share of the Company's Common Stock, par value $0.0001 per share, was either (x) purchased for $21.50 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement, or (y) automatically converted into the right to receive the Offer Price (the "Merger Consideration"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement. F5: Represents shares held by The Melissa Bender 2022 Grantor Retained Annuity Trust under Irrevocable Trust Agreement dated March 29, 2022 of which the Reporting Person's spouse is trustee.
Common StockSEC Table I · non-derivative	IndirectSee footnote	Reported balance After 2026-04-23 transaction · row 5 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 5 · 2026-04-23 · Disposition to issuer · Disposed 18,197 · Balance 0 F1: On March 6, 2026, Servier Pharmaceuticals LLC, a Delaware limited liability company ("Parent"), Servier Detroit Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Day One Biopharmaceuticals, Inc., a Delaware corporation (the "Company"), and Servier S.A.S., a French societe par actions simplifiee, solely as a guarantor, entered into an Agreement and Plan of Merger (the "Merger Agreement"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (such merger and the other transactions contemplated by the Merger Agreement, the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent. F2: Upon the closing of the Merger on April 23, 2026, each issued and outstanding share of the Company's Common Stock, par value $0.0001 per share, was either (x) purchased for $21.50 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement, or (y) automatically converted into the right to receive the Offer Price (the "Merger Consideration"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement. F6: Represents shares held by The Melissa Bender 2023 Grantor Retained Annuity Trust, dated June 27, 2023.
Common StockSEC Table I · non-derivative	IndirectSee footnote	Reported balance After 2026-04-23 transaction · row 6 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 6 · 2026-04-23 · Disposition to issuer · Disposed 300,000 · Balance 0 F1: On March 6, 2026, Servier Pharmaceuticals LLC, a Delaware limited liability company ("Parent"), Servier Detroit Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Day One Biopharmaceuticals, Inc., a Delaware corporation (the "Company"), and Servier S.A.S., a French societe par actions simplifiee, solely as a guarantor, entered into an Agreement and Plan of Merger (the "Merger Agreement"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (such merger and the other transactions contemplated by the Merger Agreement, the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent. F2: Upon the closing of the Merger on April 23, 2026, each issued and outstanding share of the Company's Common Stock, par value $0.0001 per share, was either (x) purchased for $21.50 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement, or (y) automatically converted into the right to receive the Offer Price (the "Merger Consideration"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement. F7: Represents shares held by the Melissa Bender 2025 Grantor Retained Annuity Trust of which the Reporting Person's spouse is trustee.
Common StockSEC Table I · non-derivative	IndirectSee footnote	Reported balance After 2026-04-23 transaction · row 7 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 7 · 2026-04-23 · Disposition to issuer · Disposed 808,285 · Balance 0 F1: On March 6, 2026, Servier Pharmaceuticals LLC, a Delaware limited liability company ("Parent"), Servier Detroit Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Day One Biopharmaceuticals, Inc., a Delaware corporation (the "Company"), and Servier S.A.S., a French societe par actions simplifiee, solely as a guarantor, entered into an Agreement and Plan of Merger (the "Merger Agreement"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (such merger and the other transactions contemplated by the Merger Agreement, the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent. F2: Upon the closing of the Merger on April 23, 2026, each issued and outstanding share of the Company's Common Stock, par value $0.0001 per share, was either (x) purchased for $21.50 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement, or (y) automatically converted into the right to receive the Offer Price (the "Merger Consideration"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement. F8: Represents shares held by the Bender Revocable Trust dated January 18, 2017, as amended, Jeremy Bender and Melissa C. Bender, Trustees.
Stock Option (right to buy Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $8.99 · Expires 2031-05-25	Direct	Reported balance After 2026-04-23 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2026-04-23 · Disposition to issuer · Disposed 1,463,134 · Balance 0 F10: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F9: The options are fully vested.
Stock Option (right to buy Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $8.99 · Expires 2032-01-17	Direct	Reported balance After 2026-04-23 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2026-04-23 · Disposition to issuer · Disposed 397,000 · Balance 0 F10: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F11: The option vests as to 2.0833% of the total shares monthly, with 100% of the total shares vested on January 18, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Stock Option (right to buy Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $8.99 · Expires 2033-01-16	Direct	Reported balance After 2026-04-23 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2026-04-23 · Disposition to issuer · Disposed 244,000 · Balance 0 F10: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F12: The option vests as to 1/48th of the total shares monthly, commencing February 17, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Stock Option (right to buy Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $8.99 · Expires 2034-01-04	Direct	Reported balance After 2026-04-23 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2026-04-23 · Disposition to issuer · Disposed 286,000 · Balance 0 F10: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F13: The option vests as to 1/48th of the total shares monthly, commencing February 5, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Stock Option (right to buy Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $8.99 · Expires 2035-01-14	Direct	Reported balance After 2026-04-23 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2026-04-23 · Disposition to issuer · Disposed 286,000 · Balance 0 F10: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F14: The option vests as to 1/48th of the total shares monthly, commencing February 15, 2025, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Stock Option (right to buy Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $11.16 · Expires 2036-01-29	Direct	Reported balance After 2026-04-23 transaction · row 13 Instrument identity requires review; Table II rows are not merged. 1 source row Row 13 · 2026-04-23 · Disposition to issuer · Disposed 355,000 · Balance 0 F10: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F15: The option vests as to 1/48th of the total shares monthly, commencing February 28, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Restricted Stock Unit (RSU)SEC Table II · derivative / convertible security	Direct	Reported balance After 2026-04-23 transaction · row 14 Instrument identity requires review; Table II rows are not merged. 1 source row Row 14 · 2026-04-23 · Disposition to issuer · Disposed 14,250 · Balance 0 F16: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. F10: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F17: The RSUs vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F18: RSUs do not expire; they either vest or are canceled prior to the vesting date.
Restricted Stock Unit (RSU)SEC Table II · derivative / convertible security	Direct	Reported balance After 2026-04-23 transaction · row 15 Instrument identity requires review; Table II rows are not merged. 1 source row Row 15 · 2026-04-23 · Disposition to issuer · Disposed 81,816 · Balance 0 F16: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. F10: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F17: The RSUs vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F18: RSUs do not expire; they either vest or are canceled prior to the vesting date.
Restricted Stock Unit (RSU)SEC Table II · derivative / convertible security	Direct	Reported balance After 2026-04-23 transaction · row 16 Instrument identity requires review; Table II rows are not merged. 1 source row Row 16 · 2026-04-23 · Disposition to issuer · Disposed 128,565 · Balance 0 F16: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. F10: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F17: The RSUs vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F18: RSUs do not expire; they either vest or are canceled prior to the vesting date.
Restricted Stock Unit (RSU)SEC Table II · derivative / convertible security	Direct	Reported balance After 2026-04-23 transaction · row 17 Instrument identity requires review; Table II rows are not merged. 1 source row Row 17 · 2026-04-23 · Disposition to issuer · Disposed 222,188 · Balance 0 F16: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. F10: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F17: The RSUs vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F18: RSUs do not expire; they either vest or are canceled prior to the vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: On March 6, 2026, Servier Pharmaceuticals LLC, a Delaware limited liability company ("Parent"), Servier Detroit Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Day One Biopharmaceuticals, Inc., a Delaware corporation (the "Company"), and Servier S.A.S., a French societe par actions simplifiee, solely as a guarantor, entered into an Agreement and Plan of Merger (the "Merger Agreement"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (such merger and the other transactions contemplated by the Merger Agreement, the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent.

F2: Upon the closing of the Merger on April 23, 2026, each issued and outstanding share of the Company's Common Stock, par value $0.0001 per share, was either (x) purchased for $21.50 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement, or (y) automatically converted into the right to receive the Offer Price (the "Merger Consideration"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement.

F3: Represents shares held by The Jeremy Bender 2023 Grantor Retained Annuity Trust dated June 27, 2023.

F4: Represents shares held by the Jeremy Bender 2025 Grantor Retained Annuity Trust of which the Reporting Person is trustee.

F5: Represents shares held by The Melissa Bender 2022 Grantor Retained Annuity Trust under Irrevocable Trust Agreement dated March 29, 2022 of which the Reporting Person's spouse is trustee.

F6: Represents shares held by The Melissa Bender 2023 Grantor Retained Annuity Trust, dated June 27, 2023.

F7: Represents shares held by the Melissa Bender 2025 Grantor Retained Annuity Trust of which the Reporting Person's spouse is trustee.

F8: Represents shares held by the Bender Revocable Trust dated January 18, 2017, as amended, Jeremy Bender and Melissa C. Bender, Trustees.

F9: The options are fully vested.

F10: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes.

F11: The option vests as to 2.0833% of the total shares monthly, with 100% of the total shares vested on January 18, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

F12: The option vests as to 1/48th of the total shares monthly, commencing February 17, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

F13: The option vests as to 1/48th of the total shares monthly, commencing February 5, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

F14: The option vests as to 1/48th of the total shares monthly, commencing February 15, 2025, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

F15: The option vests as to 1/48th of the total shares monthly, commencing February 28, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

F16: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement.

F17: The RSUs vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

F18: RSUs do not expire; they either vest or are canceled prior to the vesting date.

Fusion Pharmaceuticals Inc.

Report date June 04, 2024 · Filed June 04, 2024

Section 16 reporting ended · disclosed 2024-06-04. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.16	Direct	0	Reported balance After 2024-06-04 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2024-06-04 · Disposition to issuer · Disposed 34,000 · Balance 0 F1: Pursuant to the Arrangement Agreement, dated as of March 18, 2024 (the "Arrangement Agreement"), by and among the Issuer, AstraZeneca AB, a public company with limited liability (Aktiebolag) incorporated under the laws of Sweden ("Parent") and 15863210 Canada Inc., a corporation formed under the Canada Business Corporations Act ("Purchaser"), Purchaser acquired all of the issued and outstanding common shares of the Issuer (collectively, the "Shares") effective as of 12:01 a.m. Toronto time on June 4, 2024 (the "Effective Time"). Following the Effective Time, each Share outstanding immediately prior to the Effective Time was assigned and transferred by the holder thereof to Purchaser in exchange for (i) US$21.00 in cash (the "Cash Consideration") plus (ii) one contingent value right (each, a "CVR") representing the contingent right to receive a cash payment equal to US$3.00, in each case subject to applicable tax withholdings and other source deductions. F2: Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an "Option") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Arrangement Agreement, dated as of March 18, 2024 (the "Arrangement Agreement"), by and among the Issuer, AstraZeneca AB, a public company with limited liability (Aktiebolag) incorporated under the laws of Sweden ("Parent") and 15863210 Canada Inc., a corporation formed under the Canada Business Corporations Act ("Purchaser"), Purchaser acquired all of the issued and outstanding common shares of the Issuer (collectively, the "Shares") effective as of 12:01 a.m. Toronto time on June 4, 2024 (the "Effective Time"). Following the Effective Time, each Share outstanding immediately prior to the Effective Time was assigned and transferred by the holder thereof to Purchaser in exchange for (i) US$21.00 in cash (the "Cash Consideration") plus (ii) one contingent value right (each, a "CVR") representing the contingent right to receive a cash payment equal to US$3.00, in each case subject to applicable tax withholdings and other source deductions.

F2: Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an "Option") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
November 15, 2024 Filed Nov 19, 2024 21:36 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Exercise / conversionCommon Stock	11,687	Not disclosed	Not disclosed	Disclosure SEC source: 0001415889-24-027239 · form4-11192024_091115.xml · nonDerivative · entry 3 Bender Jeremy · CIK 0001863107 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 118,931 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document
November 15, 2024 Filed Nov 19, 2024 21:36 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Exercise / conversionCommon Stock	4,750	Not disclosed	Not disclosed	Disclosure SEC source: 0001415889-24-027239 · form4-11192024_091115.xml · nonDerivative · entry 2 Bender Jeremy · CIK 0001863107 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 107,244 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document
November 15, 2024 Filed Nov 19, 2024 21:36 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Exercise / conversionCommon Stock	3,562	Not disclosed	Not disclosed	Disclosure SEC source: 0001415889-24-027239 · form4-11192024_091115.xml · nonDerivative · entry 1 Bender Jeremy · CIK 0001863107 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 102,494 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document
August 16, 2024 Filed Aug 19, 2024 21:53 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	SaleCommon Stock	10,681	$14.00	$149,524.39	Disclosure SEC source: 0001415889-24-021617 · form4-08192024_090834.xml · nonDerivative · entry 4 Bender Jeremy · CIK 0001863107 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 98,932 F2 · kind: The sale of shares is for the sole purpose of covering the Reporting Person's tax liability with respect to the settlement of RSUs. Read SEC document
August 15, 2024 Filed Aug 19, 2024 21:53 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Exercise / conversionRestricted Stock Unit (RSU) · Derivative	11,687	$0.00	$0.00	Disclosure SEC source: 0001415889-24-021617 · form4-08192024_090834.xml · derivative · entry 12 Bender Jeremy · CIK 0001863107 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 151,939 Underlying: Common Stock · 11,687 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F8 · derivative.exercise_date: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F8 · derivative.expiration_date: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document
August 15, 2024 Filed Aug 19, 2024 21:53 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Exercise / conversionRestricted Stock Unit (RSU) · Derivative	4,750	$0.00	$0.00	Disclosure SEC source: 0001415889-24-021617 · form4-08192024_090834.xml · derivative · entry 11 Bender Jeremy · CIK 0001863107 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,750 Underlying: Common Stock · 4,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F8 · derivative.exercise_date: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F8 · derivative.expiration_date: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document
August 15, 2024 Filed Aug 19, 2024 21:53 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Exercise / conversionRestricted Stock Unit (RSU) · Derivative	3,562	$0.00	$0.00	Disclosure SEC source: 0001415889-24-021617 · form4-08192024_090834.xml · derivative · entry 10 Bender Jeremy · CIK 0001863107 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,818 Underlying: Common Stock · 3,562 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F8 · derivative.exercise_date: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F8 · derivative.expiration_date: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document
August 15, 2024 Filed Aug 19, 2024 21:53 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Exercise / conversionCommon Stock	11,687	Not disclosed	Not disclosed	Disclosure SEC source: 0001415889-24-021617 · form4-08192024_090834.xml · nonDerivative · entry 3 Bender Jeremy · CIK 0001863107 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 109,613 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document
August 15, 2024 Filed Aug 19, 2024 21:53 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Exercise / conversionCommon Stock	4,750	Not disclosed	Not disclosed	Disclosure SEC source: 0001415889-24-021617 · form4-08192024_090834.xml · nonDerivative · entry 2 Bender Jeremy · CIK 0001863107 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 97,926 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document
August 15, 2024 Filed Aug 19, 2024 21:53 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Exercise / conversionCommon Stock	3,562	Not disclosed	Not disclosed	Disclosure SEC source: 0001415889-24-021617 · form4-08192024_090834.xml · nonDerivative · entry 1 Bender Jeremy · CIK 0001863107 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,176 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document
July 02, 2024 Filed Jul 5, 2024 22:11 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	GiftCommon Stock	72,612	$0.00	$0.00	Disclosure SEC source: 0001415889-24-019309 · form4-07052024_100707.xml · nonDerivative · entry 8 Bender Jeremy · CIK 0001863107 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Indirect · By Bender Revocable Trust Disclosed balance after: 807,026 F9 · shares: Represents an annuity payment made by The Melissa Bender 2023 Grantor Retained Annuity Trust, dated June 27, 2023 ("Melissa Bender 2023 GRAT"), which was transferred by the Reporting Person as a bona fide gift for no consideration to the Bender Revocable Trust dated January 18, 2017. F4 · ownership.nature: Represents shares held by the Bender Revocable Trust dated January 18, 2017. Read SEC document
July 02, 2024 Filed Jul 5, 2024 22:11 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	GiftCommon Stock	72,612	$0.00	$0.00	Disclosure SEC source: 0001415889-24-019309 · form4-07052024_100707.xml · nonDerivative · entry 7 Bender Jeremy · CIK 0001863107 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 197,614 F9 · shares: Represents an annuity payment made by The Melissa Bender 2023 Grantor Retained Annuity Trust, dated June 27, 2023 ("Melissa Bender 2023 GRAT"), which was transferred by the Reporting Person as a bona fide gift for no consideration to the Bender Revocable Trust dated January 18, 2017. F10 · ownership.nature: Represents shares held by the Melissa Bender 2023 GRAT. Read SEC document
July 02, 2024 Filed Jul 5, 2024 22:11 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	GiftCommon Stock	80,619	$0.00	$0.00	Disclosure SEC source: 0001415889-24-019309 · form4-07052024_100707.xml · nonDerivative · entry 6 Bender Jeremy · CIK 0001863107 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Indirect · By Bender Revocable Trust Disclosed balance after: 734,414 F7 · shares: Represents an annuity payment made by The Jeremy Bender 2023 Grantor Retained Annuity Trust dated June 27, 2023 ("Jeremy Bender 2023 GRAT"), which was transferred by the Reporting Person as a bona fide gift for no consideration to the Bender Revocable Trust dated January 18, 2017. F4 · ownership.nature: Represents shares held by the Bender Revocable Trust dated January 18, 2017. Read SEC document
July 02, 2024 Filed Jul 5, 2024 22:11 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	GiftCommon Stock	80,619	$0.00	$0.00	Disclosure SEC source: 0001415889-24-019309 · form4-07052024_100707.xml · nonDerivative · entry 5 Bender Jeremy · CIK 0001863107 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 219,406 F7 · shares: Represents an annuity payment made by The Jeremy Bender 2023 Grantor Retained Annuity Trust dated June 27, 2023 ("Jeremy Bender 2023 GRAT"), which was transferred by the Reporting Person as a bona fide gift for no consideration to the Bender Revocable Trust dated January 18, 2017. F8 · ownership.nature: Represents shares held by the Jeremy Bender 2023 GRAT. Read SEC document
July 02, 2024 Filed Jul 5, 2024 22:11 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	GiftCommon Stock	29,606	$0.00	$0.00	Disclosure SEC source: 0001415889-24-019309 · form4-07052024_100707.xml · nonDerivative · entry 4 Bender Jeremy · CIK 0001863107 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Indirect · By Bender Revocable Trust Disclosed balance after: 653,795 F5 · shares: Represents an annuity payment made by The Melissa Bender 2022 Grantor Retained Annuity Trust under Irrevocable Trust Agreement dated March 29, 2022 ("Melissa Bender 2022 GRAT"), which was transferred by the Reporting Person as a bona fide gift for no consideration to the Bender Revocable Trust dated January 18, 2017. F4 · ownership.nature: Represents shares held by the Bender Revocable Trust dated January 18, 2017. Read SEC document
July 02, 2024 Filed Jul 5, 2024 22:11 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	GiftCommon Stock	29,606	$0.00	$0.00	Disclosure SEC source: 0001415889-24-019309 · form4-07052024_100707.xml · nonDerivative · entry 3 Bender Jeremy · CIK 0001863107 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 222,030 F5 · shares: Represents an annuity payment made by The Melissa Bender 2022 Grantor Retained Annuity Trust under Irrevocable Trust Agreement dated March 29, 2022 ("Melissa Bender 2022 GRAT"), which was transferred by the Reporting Person as a bona fide gift for no consideration to the Bender Revocable Trust dated January 18, 2017. F6 · ownership.nature: Represents shares held by the Melissa Bender 2022 GRAT of which the Reporting Person's spouse is trustee. Read SEC document
July 02, 2024 Filed Jul 5, 2024 22:11 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	GiftCommon Stock	59,075	$0.00	$0.00	Disclosure SEC source: 0001415889-24-019309 · form4-07052024_100707.xml · nonDerivative · entry 2 Bender Jeremy · CIK 0001863107 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Indirect · By Bender Revocable Trust Disclosed balance after: 624,189 F1 · shares: Represents an annuity payment made by The Jeremy Bender 2022 Grantor Retained Annuity Trust under Irrevocable Trust Agreement dated March 29, 2022 ("Jeremy Bender 2022 GRAT"), which was transferred by the Reporting Person as a bona fide gift for no consideration to the Bender Revocable Trust dated January 18, 2017, as amended, Jeremy Bender and Melissa C. Bender, Trustees ("Bender Revocable Trust dated January 18, 2017"). F3 · balance_after: Includes 565,114 shares of the Issuer's Common Stock that the Reporting Person retitled on July 2, 2024. F4 · ownership.nature: Represents shares held by the Bender Revocable Trust dated January 18, 2017. Read SEC document
July 02, 2024 Filed Jul 5, 2024 22:11 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	GiftCommon Stock	59,075	$0.00	$0.00	Disclosure SEC source: 0001415889-24-019309 · form4-07052024_100707.xml · nonDerivative · entry 1 Bender Jeremy · CIK 0001863107 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 162,762 F1 · shares: Represents an annuity payment made by The Jeremy Bender 2022 Grantor Retained Annuity Trust under Irrevocable Trust Agreement dated March 29, 2022 ("Jeremy Bender 2022 GRAT"), which was transferred by the Reporting Person as a bona fide gift for no consideration to the Bender Revocable Trust dated January 18, 2017, as amended, Jeremy Bender and Melissa C. Bender, Trustees ("Bender Revocable Trust dated January 18, 2017"). F2 · ownership.nature: Represents shares held by the Jeremy Bender 2022 GRAT of which the Reporting Person is trustee. Read SEC document
July 02, 2024 Filed Jul 14, 2025 20:18 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	GiftCommon Stock	199,202	$0.00	$0.00	Disclosure SEC source: 0001415889-25-019707 · form4-07142025_080742.xml · nonDerivative · entry 6 Bender Jeremy · CIK 0001863107 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Indirect · By Bender Revocable Trust Disclosed balance after: 1,228,868 F6 · shares: Represents an annuity payment made by The Jeremy Bender 2023 Grantor Retained Annuity Trust dated June 27, 2023 ("Jeremy Bender 2023 GRAT"), which was transferred by the Reporting Person as a bona fide gift for no consideration to the Bender Revocable Trust dated January 18, 2017. F3 · ownership.nature: Represents shares held by the Bender Revocable Trust dated January 18, 2017. Read SEC document
June 17, 2024 Filed Jun 17, 2024 20:15 UTC	Mereo BioPharma Group plc MREO · Entity 7264	GrantAmerican Depositary Shares representing Ordinary Shares	12,550	$3.99	$50,074.50	Disclosure SEC source: 0000950170-24-074247 · ownership.xml · nonDerivative · entry 1 Bender Jeremy · CIK 0001863107 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · THE BENDER TRUST UAD 01/18/17 Disclosed balance after: 12,550 F1 · security: Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer. Read SEC document
June 04, 2024 Filed Jun 4, 2024 21:23 UTC	Fusion Pharmaceuticals Inc. FUSN · Entity 11851	Disposition to issuerStock Option (Right to Buy) · Derivative	34,000	Not disclosed Strike: $4.16	Not disclosed	Disclosure SEC source: 0000950170-24-068888 · ownership.xml · derivative · entry 1 Bender Jeremy · CIK 0001863107 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 34,000 shares Expires not disclosed F1 · security: Pursuant to the Arrangement Agreement, dated as of March 18, 2024 (the "Arrangement Agreement"), by and among the Issuer, AstraZeneca AB, a public company with limited liability (Aktiebolag) incorporated under the laws of Sweden ("Parent") and 15863210 Canada Inc., a corporation formed under the Canada Business Corporations Act ("Purchaser"), Purchaser acquired all of the issued and outstanding common shares of the Issuer (collectively, the "Shares") effective as of 12:01 a.m. Toronto time on June 4, 2024 (the "Effective Time"). Following the Effective Time, each Share outstanding immediately prior to the Effective Time was assigned and transferred by the holder thereof to Purchaser in exchange for (i) US$21.00 in cash (the "Cash Consideration") plus (ii) one contingent value right (each, a "CVR") representing the contingent right to receive a cash payment equal to US$3.00, in each case subject to applicable tax withholdings and other source deductions. F2 · price: Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an "Option") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions. F2 · derivative.exercise_date: Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an "Option") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions. F2 · derivative.expiration_date: Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an "Option") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions. Read SEC document
May 16, 2024 Filed May 17, 2024 22:27 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	SaleCommon Stock	7,873	$16.08	$126,587.61	Disclosure SEC source: 0001415889-24-013620 · form4-05172024_100527.xml · nonDerivative · entry 4 Bender Jeremy · CIK 0001863107 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 654,728 F2 · kind: The sale of shares is for the sole purpose of covering the Reporting Person's tax liability with respect to the settlement of RSUs. Read SEC document
May 15, 2024 Filed May 17, 2024 22:27 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Exercise / conversionRestricted Stock Unit (RSU) · Derivative	11,687	$0.00	$0.00	Disclosure SEC source: 0001415889-24-013620 · form4-05172024_100527.xml · derivative · entry 11 Bender Jeremy · CIK 0001863107 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 163,626 Underlying: Common Stock · 11,687 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F7 · derivative.exercise_date: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F7 · derivative.expiration_date: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document
May 15, 2024 Filed May 17, 2024 22:27 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Exercise / conversionRestricted Stock Unit (RSU) · Derivative	4,750	$0.00	$0.00	Disclosure SEC source: 0001415889-24-013620 · form4-05172024_100527.xml · derivative · entry 10 Bender Jeremy · CIK 0001863107 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,500 Underlying: Common Stock · 4,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F7 · derivative.exercise_date: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F7 · derivative.expiration_date: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document
May 15, 2024 Filed May 17, 2024 22:27 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Exercise / conversionRestricted Stock Unit (RSU) · Derivative	3,562	$0.00	$0.00	Disclosure SEC source: 0001415889-24-013620 · form4-05172024_100527.xml · derivative · entry 9 Bender Jeremy · CIK 0001863107 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,380 Underlying: Common Stock · 3,562 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F7 · derivative.exercise_date: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F7 · derivative.expiration_date: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document
May 15, 2024 Filed May 17, 2024 22:27 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Exercise / conversionCommon Stock	11,687	Not disclosed	Not disclosed	Disclosure SEC source: 0001415889-24-013620 · form4-05172024_100527.xml · nonDerivative · entry 3 Bender Jeremy · CIK 0001863107 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 662,601 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document
May 15, 2024 Filed May 17, 2024 22:27 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Exercise / conversionCommon Stock	4,750	Not disclosed	Not disclosed	Disclosure SEC source: 0001415889-24-013620 · form4-05172024_100527.xml · nonDerivative · entry 2 Bender Jeremy · CIK 0001863107 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 650,914 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document
May 15, 2024 Filed May 17, 2024 22:27 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Exercise / conversionCommon Stock	3,562	Not disclosed	Not disclosed	Disclosure SEC source: 0001415889-24-013620 · form4-05172024_100527.xml · nonDerivative · entry 1 Bender Jeremy · CIK 0001863107 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 646,164 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document
May 03, 2024 Filed May 3, 2024 22:48 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	SaleCommon Stock	9,154	$17.85	$163,417.21	Disclosure SEC source: 0001415889-24-012255 · form4-05032024_100509.xml · nonDerivative · entry 3 Bender Jeremy · CIK 0001863107 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 642,602 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 3, 2023. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.84 to $17.96 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
May 02, 2024 Filed May 3, 2024 22:48 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	SaleCommon Stock	6	$17.94	$107.63	Disclosure SEC source: 0001415889-24-012255 · form4-05032024_100509.xml · nonDerivative · entry 2 Bender Jeremy · CIK 0001863107 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 651,756 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 3, 2023. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.85 to $17.955 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
May 01, 2024 Filed May 3, 2024 22:48 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	SaleCommon Stock	70,051	$17.88	$1,252,182.64	Disclosure SEC source: 0001415889-24-012255 · form4-05032024_100509.xml · nonDerivative · entry 1 Bender Jeremy · CIK 0001863107 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 651,762 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 3, 2023. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.84 to $18.04 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
February 16, 2024 Filed Feb 20, 2024 23:14 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	SaleCommon Stock	7,615	$15.25	$116,114.28	Disclosure SEC source: 0001415889-24-004452 · form4-02202024_110237.xml · nonDerivative · entry 4 Bender Jeremy · CIK 0001863107 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 721,813 F2 · kind: The sale of shares is for the sole purpose of covering the Reporting Person's tax liability with respect to the settlement of RSUs. Read SEC document
February 15, 2024 Filed Feb 20, 2024 23:14 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Exercise / conversionRestricted Stock Unit (RSU) · Derivative	11,687	$0.00	$0.00	Disclosure SEC source: 0001415889-24-004452 · form4-02202024_110237.xml · derivative · entry 11 Bender Jeremy · CIK 0001863107 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 175,313 Underlying: Common Stock · 11,687 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F7 · derivative.exercise_date: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F7 · derivative.expiration_date: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document
February 15, 2024 Filed Feb 20, 2024 23:14 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Exercise / conversionRestricted Stock Unit (RSU) · Derivative	4,750	$0.00	$0.00	Disclosure SEC source: 0001415889-24-004452 · form4-02202024_110237.xml · derivative · entry 10 Bender Jeremy · CIK 0001863107 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,250 Underlying: Common Stock · 4,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F7 · derivative.exercise_date: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F7 · derivative.expiration_date: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document
February 15, 2024 Filed Feb 20, 2024 23:14 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Exercise / conversionRestricted Stock Unit (RSU) · Derivative	3,562	$0.00	$0.00	Disclosure SEC source: 0001415889-24-004452 · form4-02202024_110237.xml · derivative · entry 9 Bender Jeremy · CIK 0001863107 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,942 Underlying: Common Stock · 3,562 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F7 · derivative.exercise_date: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F7 · derivative.expiration_date: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document
February 15, 2024 Filed Feb 20, 2024 23:14 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Exercise / conversionCommon Stock	11,687	Not disclosed	Not disclosed	Disclosure SEC source: 0001415889-24-004452 · form4-02202024_110237.xml · nonDerivative · entry 3 Bender Jeremy · CIK 0001863107 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 729,428 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document
February 15, 2024 Filed Feb 20, 2024 23:14 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Exercise / conversionCommon Stock	4,750	Not disclosed	Not disclosed	Disclosure SEC source: 0001415889-24-004452 · form4-02202024_110237.xml · nonDerivative · entry 2 Bender Jeremy · CIK 0001863107 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 717,741 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document
February 15, 2024 Filed Feb 20, 2024 23:14 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Exercise / conversionCommon Stock	3,562	Not disclosed	Not disclosed	Disclosure SEC source: 0001415889-24-004452 · form4-02202024_110237.xml · nonDerivative · entry 1 Bender Jeremy · CIK 0001863107 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 712,991 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document
February 08, 2024 Filed Feb 9, 2024 21:15 UTC	Mereo BioPharma Group plc MREO · Entity 7264	GrantDeferred Restricted Stock Units · Derivative	16,361	Not disclosed	Not disclosed	Disclosure SEC source: 0000950170-24-013268 · ownership.xml · derivative · entry 2 Bender Jeremy · CIK 0001863107 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,361 Underlying: American Depository Shares · 16,361 shares Expires not disclosed F3 · derivative.exercise_price: Deferred restricted stock units ("DRSU") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service. F3 · price: Deferred restricted stock units ("DRSU") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service. F3 · derivative.exercise_date: Deferred restricted stock units ("DRSU") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service. F3 · derivative.expiration_date: Deferred restricted stock units ("DRSU") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service. F2 · derivative.underlying: Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer. Read SEC document
February 08, 2024 Filed Feb 9, 2024 21:15 UTC	Mereo BioPharma Group plc MREO · Entity 7264	GrantShare Options (Right to buy) · Derivative	45,000	$0.00 Strike: $3.87	$0.00	Disclosure SEC source: 0000950170-24-013268 · ownership.xml · derivative · entry 1 Bender Jeremy · CIK 0001863107 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,000 Underlying: American Depository Shares · 45,000 shares Expires 2034-02-08 F1 · derivative.exercise_date: Vests in substantially equal monthly installments over a one year period from the February 8, 2024 grant date. F2 · derivative.underlying: Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer. Read SEC document
January 05, 2024 Filed Jan 10, 2024 00:17 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	GrantRestricted Stock Units · Derivative	187,000	$0.00	$0.00	Disclosure SEC source: 0001209191-24-001286 · doc4.xml · derivative · entry 2 Bender Jeremy · CIK 0001863107 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 187,000 Underlying: Common Stock · 187,000 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The RSUs vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F3 · derivative.expiration_date: The RSUs vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document
January 05, 2024 Filed Jan 10, 2024 00:17 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	GrantStock Option (right to buy Common Stock) · Derivative	286,000	$0.00 Strike: $14.44	$0.00	Disclosure SEC source: 0001209191-24-001286 · doc4.xml · derivative · entry 1 Bender Jeremy · CIK 0001863107 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 286,000 Underlying: Common Stock · 286,000 shares Expires 2034-01-04 F1 · derivative.exercise_date: The option vests as to 1/48th of the total shares monthly, commencing February 5, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document
November 16, 2023 Filed Nov 17, 2023 23:20 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	SaleCommon Stock	3,107	$11.69	$36,320.83	Disclosure SEC source: 0001209191-23-055879 · doc4.xml · nonDerivative · entry 3 Bender Jeremy · CIK 0001863107 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 709,429 F2 · kind: The sale of shares is for the sole purpose of covering the Reporting Person's tax liability with respect to the settlement of RSUs. Read SEC document
November 15, 2023 Filed Nov 17, 2023 23:20 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Exercise / conversionRestricted Stock Units · Derivative	4,750	$0.00	$0.00	Disclosure SEC source: 0001209191-23-055879 · doc4.xml · derivative · entry 9 Bender Jeremy · CIK 0001863107 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,000 Underlying: Common Stock · 4,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F7 · derivative.exercise_date: The RSUs vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F7 · derivative.expiration_date: The RSUs vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document
November 15, 2023 Filed Nov 17, 2023 23:20 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Exercise / conversionRestricted Stock Units · Derivative	3,562	$0.00	$0.00	Disclosure SEC source: 0001209191-23-055879 · doc4.xml · derivative · entry 8 Bender Jeremy · CIK 0001863107 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,504 Underlying: Common Stock · 3,562 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F7 · derivative.exercise_date: The RSUs vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F7 · derivative.expiration_date: The RSUs vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document
November 15, 2023 Filed Nov 17, 2023 23:20 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Exercise / conversionCommon Stock	4,750	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-23-055879 · doc4.xml · nonDerivative · entry 2 Bender Jeremy · CIK 0001863107 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 712,536 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document
November 15, 2023 Filed Nov 17, 2023 23:20 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Exercise / conversionCommon Stock	3,562	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-23-055879 · doc4.xml · nonDerivative · entry 1 Bender Jeremy · CIK 0001863107 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 707,786 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document
October 16, 2023 Filed Oct 16, 2023 20:58 UTC	Fusion Pharmaceuticals Inc. FUSN · Entity 11851	GrantStock Option (Right to Buy) · Derivative	34,000	$0.00 Strike: $4.16	$0.00	Disclosure SEC source: 0001209191-23-052877 · doc4.xml · derivative · entry 1 Bender Jeremy · CIK 0001863107 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,000 Underlying: Common Stock · 34,000 shares Expires 2033-10-16 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in 36 substantially equal monthly installments starting on November 16, 2023. Read SEC document
August 17, 2023 Filed Aug 17, 2023 22:16 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	SaleCommon Stock	2,996	$13.86	$41,524.56	Disclosure SEC source: 0001209191-23-046409 · doc4.xml · nonDerivative · entry 3 Bender Jeremy · CIK 0001863107 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 704,224 F2 · kind: The sale of shares is for the sole purpose of covering the Reporting Person's tax liability with respect to the settlement of RSUs. Read SEC document
August 15, 2023 Filed Aug 17, 2023 22:16 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Exercise / conversionRestricted Stock Units · Derivative	4,750	$0.00	$0.00	Disclosure SEC source: 0001209191-23-046409 · doc4.xml · derivative · entry 9 Bender Jeremy · CIK 0001863107 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,750 Underlying: Common Stock · 4,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F7 · derivative.exercise_date: The RSUs vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F7 · derivative.expiration_date: The RSUs vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.